Danish biotech firm Genmab and US drugmaker AbbVie said on Monday ​their combination treatment for patients newly diagnosed with ‌a type of lymphoma reduced the risk of disease progression or death in a late-stage study.

Log in or sign up to comment.

No comments yet.

← Back to stories